Brainsway (NASDAQ:BWAY) Stock Rating Upgraded by Zacks Research

Key Points

• Zacks Research upgraded Brainsway (BWAY) from "hold" to "strong-buy" and other firms have moved their ratings, leaving an average analyst rating of Buy with an average price target of $15.00 (HC Wainwright recently cut its target to $15).
• Recent quarter beat expectations — EPS $0.14 vs. $0.11 expected and revenue $14.55M vs. $14.02M — and the stock is trading near its 12‑month high (opened around $13.86) with a market cap of about $544M and a PE of 55.44.
• Company focus: Brainsway develops deep transcranial magnetic stimulation (Deep TMS) devices for non‑invasive neuromodulation to treat neuropsychiatric and neurological disorders.

Brainsway (NASDAQ:BWAY - Get Free Report) was upgraded by equities research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research note issued on Tuesday,Zacks.com reports.

A number of other research analysts also recently issued reports on BWAY. Wall Street Zen raised Brainsway from a "hold" rating to a "buy" rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Brainsway in a report on Monday, December 29th. Northland Securities set a $15.00 price target on Brainsway in a research note on Thursday, January 22nd. Finally, HC Wainwright cut their price target on Brainsway from $30.00 to $15.00 and set a "buy" rating on the stock in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $15.00.

Brainsway Stock Up 2.7%

BWAY opened at $13.86 on Tuesday. Brainsway has a twelve month low of $3.92 and a twelve month high of $14.65. The company has a fifty day moving average of $12.49 and a 200-day moving average of $9.87. The stock has a market cap of $544.28 million, a PE ratio of 55.44 and a beta of 1.20.

Brainsway (NASDAQ:BWAY - Get Free Report) last released its earnings results on Wednesday, March 11th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.03. Brainsway had a net margin of 14.62% and a return on equity of 11.10%. The business had revenue of $14.55 million for the quarter, compared to analyst estimates of $14.02 million. Sell-side analysts anticipate that Brainsway will post 0.08 EPS for the current fiscal year.

Institutional Trading of Brainsway

Large investors have recently made changes to their positions in the company. Bullseye Asset Management LLC bought a new position in Brainsway in the fourth quarter worth approximately $299,000. Legato Capital Management LLC increased its holdings in shares of Brainsway by 9.3% during the fourth quarter. Legato Capital Management LLC now owns 97,376 shares of the company's stock valued at $1,852,000 after acquiring an additional 8,295 shares in the last quarter. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Brainsway during the fourth quarter valued at approximately $209,000. Sigma Planning Corp acquired a new position in shares of Brainsway during the fourth quarter worth approximately $285,000. Finally, Huntleigh Advisors Inc. lifted its holdings in shares of Brainsway by 5.8% in the 4th quarter. Huntleigh Advisors Inc. now owns 87,076 shares of the company's stock worth $1,656,000 after purchasing an additional 4,811 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors and hedge funds.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway's technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company's flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.